Identification of prognostic biomarkers for prostate cancer

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1734-1743

  Kosari, Farhad ^a,b   Munz, Jan Marie A ^a,b   Savci Heijink, C Dilara ^a,b   Spiro, Craig ^a,b   Klee, Eric W ^a,b   Kube, Dagmar Marie ^a   Tillmans, Lori ^a,b   Slezak, Jeff ^a,b   Karnes, R Jeffrey ^a,b   Cheville, John C ^a,c   Vasmatzis, George ^a,c  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; FOLLOW UP; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GLEASON SCORE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE;

ANTIGENS, NEOPLASM; AUTOMATIC DATA PROCESSING; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 41549090588     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1494     Document Type: Article

References (32)

1. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306.
2. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-25.
3. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995-1000.
4. Epstein JI, Amin M, Boccon-Gibod L, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005;216:34-63.
5. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000;56:823-7.
6. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
7. Tibshirani R, Hastie T. Outlier sums for differential gene expression analysis. Biostatistics 2007;8:2-8.
8. Wu B. Cancer outlier differential gene expression detection. Biostatistics 2006;8:3.
9. Kube DM, Savci-Heijink CD, Lamblin AF, et al. Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer. BMC Mol Biol 2007;8:25.
10. Rubin MA, Bismar TA, Andren O, et al. Decreased α-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14:1424-32.
11. Tabach Y, Milyavsky M, Shats I, et al. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Mol Syst Biol 2005;1:2005-22.
12. Schmidt U, Fuessel S, Koch R, et al. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006;66:1521-34.
13. True L, Coleman I, Hawley S, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 2006;103:10991-6.
14. Hughes C, Murphy A, Martin C, et al. Topoisomerase II-α expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma. J Clin Pathol 2006;59:721-4.
15. Best CJ, Gillespie JW, Yi Y, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005;11:6823-34.
16. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
17. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
18. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:31.
19. Nam RK, Sugar L, Wang Z, et al. Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007;6:40-5.
20. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-51.
21. Ramachandran S, Liu P, Young AN, et al. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 2005;24:188-98.
22. Milyavsky M, Tabach Y, Shats I, et al. Transcriptional programs following genetic alterations in p53, INK4A, H-Ras genes along defined stages of malignant transformation. Cancer Res 2005;65:4530-43.
23. O'Connor JK, Hazard LJ, Avent JM, Lee RJ, Fischbach J, Gaffney DK. Topoisomerase II α expression correlates with diminished disease-free survival in invasive breast cancer. Int J Radiat Oncol Biol Phys 2006;65:1411-5.
24. Rosty C, Sheffer M, Tsafrir D, et al. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 2005;24:7094-104.
25. Brustmann H. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II α and prognosis. Gynecol Oncol 2004;95:16-22.
26. Reubi JC, Laissue JA. Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 1995;16:110-5.
27. Liu Y. Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions. Cancer Lett 2006;239:21-6.
28. Straume O, Akslen LA. Increased expression of VEGF-receptors (FLT-1, KDR, NRP1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. Angiogenesis 2003;6:295-301.
29. Latil A, Bieche I, Pesche S, et al. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 2000;89:167-71.
30. Qi L, Robinson WA, Brady BM, Glode LM. Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Anticancer Res 2003;23:3917-22.
31. Ribeiro FR, Diep CB, Jeronimo C, et al. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 2006;45:154-63.
32. Ribeiro FR, Jeronimo C, Henrique R, et al. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 2006;12:3961-70.